Molecular Templates Dirección

Dirección controles de criterios 2/4

El CEO de Molecular Templates' es Eric Poma , nombrado en Jan 2009, tiene una permanencia de 14.83 años. compensación anual total es $1.55M, compuesta por 38.8% salario y 61.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.34% de las acciones de la empresa, por valor de €89.29K. La antigüedad media del equipo directivo y de la junta directiva es de 0.3 años y 6.3 años, respectivamente.

Información clave

Eric Poma

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	38.8%
Permanencia del CEO	14.8yrs
Participación del CEO	0.3%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Poma en comparación con los beneficios de Molecular Templates?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$60m
Dec 31 2022	US$2m	US$600k	-US$93m
Sep 30 2022	n/a	n/a	-US$81m
Jun 30 2022	n/a	n/a	-US$87m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$4m	US$577k	-US$83m
Sep 30 2021	n/a	n/a	-US$101m
Jun 30 2021	n/a	n/a	-US$94m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	US$5m	US$560k	-US$105m
Sep 30 2020	n/a	n/a	-US$92m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$85m
Dec 31 2019	US$2m	US$515k	-US$69m
Sep 30 2019	n/a	n/a	-US$60m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$4m	US$500k	-US$30m
Sep 30 2018	n/a	n/a	-US$31m
Jun 30 2018	n/a	n/a	-US$36m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$3m	US$448k	-US$24m
Sep 30 2017	n/a	n/a	-US$20m
Jun 30 2017	n/a	n/a	-US$13m
Mar 31 2017	n/a	n/a	-US$11m
Dec 31 2016	US$607k	US$400k	-US$13m

Compensación vs. Mercado: La compensación total de Eric($USD1.55M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Eric ha sido consistente con los resultados de la empresa en el último año.

CEO

Eric Poma (51 yo)

14.8yrs

Permanencia

US$1,547,340

Compensación

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Poma	CEO, Chief Scientific Officer & Director	14.8yrs	US$1.55m	0.34% $ 89.3k
Jason Kim	President	less than a year	US$899.85k	0.12% $ 30.7k
Kristen Quigley	Chief Operating Officer	less than a year	sin datos	sin datos
Grace Kim	Chief Strategy Officer & Head of IR	less than a year	sin datos	sin datos
Joseph Phillips	Senior VP & Head of CMC Development	no data	sin datos	sin datos
Maurizio Voi	Chief Medical Officer	less than a year	sin datos	sin datos
Megan Filoon	Secretary	no data	sin datos	sin datos

0.3yrs

Permanencia media

51.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NZW no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Poma	CEO, Chief Scientific Officer & Director	6.3yrs	US$1.55m	0.34% $ 89.3k
Michel Klein	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Hoffmann	Independent Director	6.3yrs	US$65.74k	0% $ 0
Harold Selick	Independent Chairman	6.3yrs	US$90.49k	0.051% $ 13.1k
Kevin Lalande	Independent Director	6.3yrs	US$62.74k	0% $ 0
Corazon Sanders	Independent Director	3.9yrs	US$55.74k	0% $ 0
Burkhard Jansen	Member of Scientific Advisory Board	no data	sin datos	sin datos
Neil Berinstein	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jonathan Lanfear	Independent Director	5.5yrs	US$56.36k	0% $ 0
Gabriela Gruia	Director	1.7yrs	US$87.67k	0% $ 0

6.3yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de NZW se considera experimentada (6.3 años de antigüedad promedio).

Molecular Templates Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Announces Board Changes

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc. Announces the Appointment of Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

Molecular Templates, Inc. Announces Executive Changes

Recent updates

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting

Molecular Templates, Inc. Announces Board Changes

Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023

Molecular Templates, Inc. Announces the Appointment of Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates, Inc., Annual General Meeting, Oct 27, 2023

New major risk - Revenue and earnings growth

Molecular Templates Announces 1-for-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.43 loss in 2Q 2022)

Molecular Templates, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

Molecular Templates, Inc. announced that it expects to receive $40.044 million in funding from BVF Partners L.P., Adage Capital Management, L.P., Bellevue Asset Management AG

New major risk - Financial position

Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.38 loss in 1Q 2022)

Full year 2022 earnings released: US$1.65 loss per share (vs US$1.50 loss in FY 2021)

Insufficient new directors

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Molecular Templates, Inc. Announces CFO Changes

Third quarter 2022 earnings released: US$0.44 loss per share (vs US$0.54 loss in 3Q 2021)

Molecular Templates Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.28 loss in 2Q 2021)

Molecular Templates, Inc.(NasdaqGS:MTEM) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: US$0.38 loss per share (vs US$0.51 loss in 1Q 2021)

Full year 2021 earnings released: US$1.50 loss per share (vs US$2.20 loss in FY 2020)

Molecular Templates, Inc. Announces Management Appointments

Molecular Templates, Inc. Announces Management Appointments

Insufficient new directors

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.47 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.28 loss per share (vs US$0.68 loss in 2Q 2020)

CFO, Treasurer & Secretary Adam Cutler has left the company

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.51 loss per share (vs US$0.48 loss in 1Q 2020)

Molecular Templates, Inc. Expects to Generate Clinical Data

Full year 2020 earnings released: US$2.20 loss per share (vs US$1.84 loss in FY 2019)

Molecular Templates, Inc. has completed a Follow-on Equity Offering in the amount of $75.9 million.

Molecular Templates, Inc. Establishes Multi-Target Collaboration with Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer

New 90-day high: €12.40

New 90-day high: €9.35

Molecular Templates, Inc. Announces Fda Acceptance of Ind Application for Mt-6402, A Pd-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

New 90-day low: €6.65

Revenue misses expectations

Third quarter 2020 earnings released: US$0.47 loss per share

Molecular Templates, Inc. Provides Update on Its Clinical Pipeline

New 90-day low: €7.25

New 90-day low - €8.75

First half earnings released

Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 2000 Value Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad